PROK
ProKidney Corp.
NASDAQ · Healthcare · Biotechnology · US
$2.01
+4.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 818.0K | 893.0K | 76.0K | — | — |
| Cost of Revenue | 2.9M | — | — | — | — |
| Gross Profit | (2.1M) | 893.0K | 76.0K | — | — |
| Operating Expenses | |||||
| R&D Expense | 130.9M | 114.1M | 127.7M | 106.7M | 82.1M |
| SG&A Expense | 41.9M | 51.8M | 56.1M | 44.8M | 70.9M |
| General & Admin Expense | 41.9M | 51.8M | 56.1M | 44.8M | 70.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.3M | — | — | — | — |
| Total Operating Expenses | 175.2M | 165.9M | 183.8M | 151.5M | 153.0M |
| Cost and Expenses | 178.0M | 165.9M | 183.8M | 151.5M | 153.0M |
| Operating Income (EBIT) | (177.2M) | (165.0M) | (183.7M) | (151.5M) | (153.0M) |
| Non-Operating | |||||
| Interest Income | 10.5M | 13.8M | 19.8M | 22.1M | 6.0M |
| Interest Expense | 19.0K | 4.0K | 9.0K | 12.0K | 215.0K |
| Net Interest Income | 10.4M | 13.8M | 19.7M | 22.1M | 5.8M |
| Other Non-Op Income/Expense | 10.4M | 13.8M | 19.7M | 22.1M | 5.8M |
| Non-Operating Income (excl Interest) | (10.5M) | (13.8M) | (19.8M) | (22.1M) | (6.0M) |
| EBT (Pre-Tax Income) | (166.8M) | (151.2M) | (163.9M) | (129.5M) | (147.2M) |
| Income Tax Expense | (21.1M) | 414.0K | (598.0K) | 6.0M | 896.0K |
| Bottom Line | |||||
| Net Income | (86.7M) | (69.0M) | (61.2M) | (35.5M) | (108.0M) |
| Earnings from Cont. Ops | (145.7M) | (151.6M) | (163.3M) | (135.4M) | (148.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (86.7M) | (69.0M) | (61.2M) | (35.5M) | (108.0M) |
| Per Share | |||||
| Basic EPS | ($0.57) | ($0.52) | ($0.62) | ($0.57) | ($1.76) |
| Diluted EPS | ($0.57) | ($0.52) | ($0.62) | ($0.57) | ($1.76) |
| Revenue Per Share | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 186.6M | 133.9M | 97.9M | 61.7M | 61.5M |
| Diluted Shares Outstanding | 186.6M | 133.9M | 97.9M | 61.7M | 61.5M |
| Profitability Metrics | |||||
| EBITDA | (160.8M) | (144.6M) | (158.5M) | (125.6M) | (144.0M) |
| D&A | 6.0M | 6.6M | 5.4M | 3.9M | 3.0M |
| EBIT | (166.8M) | (151.2M) | (163.9M) | (129.4M) | (147.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026